International personal care giant Colgate Palmolive has announced that it is set to acquire CBD oral care company, Hello Products. It is the most recent in a wave of established health brands entering the CBD space through acquisition.
Less than three months into Illinois’ new legal adult use cannabis market, the state says its tax revenue is already exceeding expectations.
A man who was arrested for growing cannabis plants for medicinal purposes believes the law will kill him, when the Class B drug is keeping him alive.
Recently, I had a horse accident. While dismounting my boot was stuck, and by the time I freed it the horse moved – I fell, and she tapped on my leg. She didn’t put her full force, thank goodness, or my leg would have been crushed and lost.
In 2011, British Columbia citizen, Corrie Yelland, was diagnosed with anal cancer and faced with undergoing radiation, said to cause second and third degree burns vaginally, rectally, and across her buttocks; damaging her spine for life, and probably fusing shut both her vagina and rectum.
In 1975, the year I began smoking weed – was the same year my favorite Aunt Gloria started taking me into Los Angeles – to Melrose Avenue and the Zephyr Theater, a 90-seat playhouse that opened my eyes to the beauty and amazement of avant-garde in the city.
The Cannabis plant has been used for many of years as a medicinal agent in the relief of pain and seizures. It contains approximately 540 natural compounds including more than 100 that have been identified as phytocannabinoids due to their shared chemical structure. The legalization of cannabis for medicinal purposes and for recreational use in some regions will allow for much needed research on the pharmacokinetics and pharmocology of medical cannabis. This brief review focuses on the use of cannabis as a medicinal agent in the treatment of pain, epilepsy and neurodegenerative diseases. Despite the paucity of information, attention is paid to the mechanisms by which medical cannabis may act to relieve pain and seizures.
Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep. It goes on to report new information on the effects on sleep in the context of medical treatment of neuropathic pain and symptoms of multiple sclerosis, employing standardized oromucosal cannabis-based medicines containing primarily THC, CBD, or a 1 : 1 combination of the two (Sativex).
As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Δ(9)-tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes. Through the activation primarily of CB1 receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy. During the last decade, however, several studies have now shown that CB1 and CB2 receptor agonists can act as direct antitumor agents in a variety of aggressive cancers.
“Cannabinoid” is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors. Patients with malignant disease represent a cohort within health care that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options.